Business & regional news

Collaboration with health technology company Tempus seeks to identify causes for undertreatment of minority patients with heart valve disease who may benefit from minimally invasive therapies

With its Meal Detection Technology™* and autocorrections every 5 minutes, Medtronic is expanding outcomes to populations in Asia and empowering patients to achieve greater glycemic control, especially during mealtimes.

New data from Australia, Japan, India, Singapore, Hong Kong, and South Korea demonstrates the MiniMed™ 780G is driving consistent clinical outcomes in diabetes management.

Comparative data and systematic literature review released at VIVA 2024 show breadth and depth of data supporting atherectomy as a treatment for peripheral arterial disease

Newest-generation Evolut TAVI system builds on its market leading valve performance and durability with enhanced coronary access

Funding to support organisations with a mission to improve health outcomes

The VT research will provide important clinical evidence in an underserved patient population

Survey of 1,000 U.S. surgeons finds digital tech like AI and live streaming crucial to closing surgical care gaps in under-resourced regions.

Global expansion of the Avalus Ultra valve continues in Western Europe while company highlights robust, innovative Cardiac Surgery portfolio at EACTS in Lisbon

Bolsters Medtronic Cardiac Surgery’s comprehensive portfolio of cardiac surgical and respiratory innovation

Company recognized among top 52 global companies making positive social impact through core business strategy

ADAPT-PD trial methods and preliminary data published in npj Parkinson’s disease

Dr. James Porter will represent the company this week — including from the Hugo™ console to perform a live partial nephrectomy — at Europe’s biggest urology conference

Annual award celebrates companies fostering cultures of innovation

State-of-the-art facility based in Singapore aims to accelerate adoption of Robotics and AI across Southeast Asia through training and education, improving access to new healthcare technologies and delivering better care experiences across the region

The company will present clinical evidence in young children, pregnancy and type 2 diabetes*

Post-market data collection will add real-world experience to established safety, efficacy, and efficiency evidence profile

New MRI labeling extends active scan time for Medtronic DBS systems

First ever FDA approval provides more options to meet patients’ personalized needs, including those with Parkinson’s disease